For patients with relapsing-remitting multiple sclerosis (MS), rituximab is not noninferior to ocrelizumab, according to a study published online June 12 in JAMA Neurology.
Jun 14, 2023
0
2
A best treatment pathway has been identified for people with multiple sclerosis (MS) whose current medication puts them at risk of a serious brain infection.
Jun 5, 2023
0
27
(HealthDay)—For patients with primary progressive multiple sclerosis (PPMS), ocrelizumab reduces progression of upper-extremity (UE) impairment, according to an exploratory analysis published online Nov. 12 in the Multiple ...
Nov 26, 2018
0
1
In March 2017, the U.S. Food and Drug Administration approved ocrelizumab as the first treatment for both relapsing (RMS) and progressive forms of multiple sclerosis (MS), a genetic disease that afflicts approximately 400,000 ...
Apr 26, 2018
0
7
A newly approved drug that is the first to reflect the current scientific understanding of multiple sclerosis (MS) – is holding new hope for the hundreds of thousands Americans living with the disease.
Mar 29, 2017
0
8527
Three phase three clinical studies using the drug ocrelizumab to treat patients with multiple sclerosis (MS) have yielded positive results for treating two forms of the disease and the first ever positive results for a treatment ...
Oct 21, 2015
0
68
